Главная
Study mode:
on
1
Episode introduction and guest overview
2
Max's transition from DeepMind to Isomorphic Labs
3
Sergei's tech background and move to healthcare
4
Early challenges at Isomorphic Labs
5
Integrating AI into drug discovery
6
Impact of machine learning on drug design
7
Introducing AI to drug discovery teams
8
AI's role in predicting drug effects
9
Future prospects of AI in biotech
10
AI ethics in healthcare
11
Broader AI applications in healthcare
12
Reflections on AI's impact on medicine & wrap-up
Description:
Dive into a thought-provoking podcast episode exploring the intersection of artificial intelligence and drug discovery. Join host Lukas Biewald as he interviews Isomorphic Labs' Chief AI Officer Max Jaderberg and Chief Technology Officer Sergei Yakneen, both former DeepMind researchers. Discover how AI is revolutionizing the biotech industry, from molecular design to clinical trials. Gain insights into the challenges of applying machine learning to complex biological systems, the potential for AI to streamline drug development, and the ethical considerations surrounding AI in healthcare. Learn about Isomorphic Labs' innovative approach to drug discovery and the transformative impact of deep learning on the pharmaceutical industry. Explore the future of AI-driven healthcare solutions and reflect on the broader implications of artificial intelligence in medicine.

Accelerating Drug Discovery with AI - Insights from Isomorphic Labs

Weights & Biases
Add to list
0:00 / 0:00